PLX
ProtalixยทAMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PLX Profile
Protalix Biotherapeutics, Inc.
A biopharmaceutical company that uses plant cell technology to produce recombinant proteins
2 University Plaza
, Suite 100
, Hackensack
, NJ 07601
Focus on the development and commercialization of recombinant therapeutic proteins with the company's proprietary ProCellEx protein expression system.
Protalix Biotherapeutics, Inc., was originally incorporated in Florida in April 1992 and re-incorporated in Delaware in March 2016. The Company is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by the proprietary ProCellEx plant cell protein expression system. The company is the first and only FDA-approved company to express suspension proteins through plant cells. The company's unique expression system represents a new way to develop recombinant proteins on an industrial scale. The company's strategic focus is to develop custom complex recombinant therapeutic proteins produced primarily through ProCellEx, while genetically engineering and chemically modifying proteins before and after production. The company intends to carry out such engineering and modification to provide additional clinical benefits by improving the biological properties of therapeutic proteins (e.g., glycosylation, half-life, immunogenicity).
